Theralizumab Biosimilar - Research Grade [ICH5023]
Theralizumab Biosimilar - Research Grade
Product Specific Citations:
Huang et al. A bispecific antibody AP203 targeting PD-L1 and CD137 exerts potent antitumor activity without toxicity. Journal of Translational Medicine (2023).
ichorbio's theralizumab biosimilar is for Research Use Only (RUO)
ichorbio's RUO theralizumab biosimilar is available in the following sizes: 1mg, 5mg, 10mg, 20mg, 50mg, 100mg ichorbio regularly manufactures bulk multi-gram amounts of this biosimilar - please contact us for pricing.
TGN1412, CD28-SuperMAB, TAB08
Detects human CD28.
This recombinant protein was purified using multi-step affinity chromatography methods such as Protein A or G depending on the species and isotype.
Theralizumab GN1412 is a humanised monoclonal antibody that not only binds to, but is a strong agonist for, the CD28 receptor of the immune system's T cells. CD28 is the co-receptor for the T cell receptor; It binds to receptors on the interacting partner in the reaction through one of its ligands (B7 family). It was withdrawn from development after inducing severe inflammatory reactions as well as chronic organ failure in the first-in-human study by PAREXEL in London in March 2006.
1.0 - 5.0 mg/ml
Sterile, preservative-free, solution in PBS. BSA and Azide free.
>95% by SDS-PAGE and HPLC
≤ 1.0 EU/mg as determined by the LAL method
Theralizumab biosimilar - Research Grade is stable for at least four (4) weeks when stored sterile at 2-8°C. For long term storage aseptically aliquot in working volumes without diluting and store at –80°C. Avoid Repeated Freeze Thaw Cycles.
Each investigator should determine their own optimal working dilution for specific applications.
Use: ichorbio's theralizumab biosimilar is for research use only (RUO).